Invitation to submit Phase II contract, Avantgen 75N93024C00039
Past New Requirement Updated
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $1,500,000 to $3,000,000
- Set-aside
- Total Small Business
Forecast facts
- Anticipated award
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Points of contact
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The National Institutes of Health is forecasting a new requirement to invite Avantgen to submit a Phase II contract proposal under contract 75N93024C00039, with an estimated solicitation release date of 2026-11-01 and an estimated award date of 2027-07-01. The Phase II effort expands Avantgen's Phase I work, which generated and validated reagents for unique immune models used to study zoonotic diseases, into producing additional reagents for biomedical research on health and disease. The requirement is set aside for total small business under NAICS 541715, Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology).
The estimated award value range is $1.5 million to $3.0 million. The forecast's statement of impact states that non-approval would reduce the government's ability to generate reagents for unique immune models by removing the opportunity for a contractor with that capacity to submit a proposal. Points of contact are Zachary Fetters, Contracting Officer at the National Institutes of Health (zachary.fetters@nih.gov, +1 240-236-9291), and Stacy Ferguson at the National Institute of Allergy and Infectious Diseases (fergusonst@niaid.nih.gov).
Forecast text
This PCAIS entry is to request that Avantgen be invited to submit a Phase II contract proposal. This contractor provided significant benefit to the government in their prior Phase I contract by successfully generating and validating reagents needed for unique immune models for the study of zoonotic diseases. The Phase II invitation will be an expansion of these activities including generation of more unique reagents needed in the biomedical field for studying health and disease. Statement of impact: If this PCAIS entry is not approved, this will reduce the ability of the government to invest in the generation of reagents that are needed to conduct research using unique immune models that are important for studying health and disease, by not allowing a contractor with the capacity to generate the reagents the opportunity to submit a contract proposal for consideration.
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast